Merck Reports Promising HIV Treatment Data

Merck & Co., Inc.'s (MRK) HIV program has seen significant updates, according to a recent presentation at the International AIDS Conference. The company discussed phase III data from its HIV programs, including PEGASUS and VERSITRADE. Merck's PEGASUS program is focused on developing an HIV treatment that combines the use of 3TC with a booster protein.

The company reported positive results from its phase III trial for PEGASUS, showing a significant increase in viral suppression among participants. Specifically, the data showed that 85% of patients achieved undetectable levels of HIV RNA after receiving the treatment.

While the results are promising, it's essential to note that Merck has not yet received regulatory approval for its PEGASUS program. The company will need to continue gathering data and conducting further research before it can bring this potential treatment to market.